Company intelligence / Profile preview

ENA Respiratory

Melbourne, Victoria, Australiaenarespiratory.com ↗

Ownership: Private
Development stage: Phase 2

Overview

INNA-051 has demonstrated accelerated virus clearance and stimulation of antiviral host defenses in a Phase IIa proof-of-principle study using a human influenza-challenge model. A Phase 1 study in older adults (66-80 years) showed INNA-051 was well-tolerated and increased important antiviral host-defense pathways. Pre-clinical data demonstrated reduced influenza virus dissemination to the lungs of aged mice.[5][7]

Therapeutic areas: Infectious Diseases
Modalities: Small moleculesintranasal dry powder
Industry: Biotech

Drug pipeline

1 asset

INNA-051

Partnerships

COPD FoundationU.S. Department of DefenseFlu LabBLUE KNIGHT™ (Johnson & Johnson Innovation and BARDA initiative)[6][7][8]

Beyond the preview

Go deeper on ENA Respiratory.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENA Respiratory.

Explore the full profile